Page last updated: 2024-11-11

tenofovir disoproxil fumarate

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

tenofovir disoproxil fumarate : A fumarate salt prepared from equimolar amounts of tenofovir disoproxil and fumaric acid. It is used in combination therapy for the treatment of HIV infection. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID6398764
CHEMBL ID1486
CHEBI ID63718
SCHEMBL ID40021
SCHEMBL ID2670560
MeSH IDM0407969

Synonyms (96)

Synonym
tenofovir disoproxil fumarate
gs-us-104-0321
tenofovir disoproxil fumarate [usan]
viread
tenofovir df
gs-4331-05
(r)-5-((2-(6-amino-9h-purin-9-yl)-1-methylethoxy)methyl)-2,4,6,8-tetraoxa-5-phosphanonanedioic acid, bis(1-methylethyl) ester, 5-oxide, (e)-2-butenedioate (1:1)
hsdb 7165
9-((r)-2-((bis(((isopropoxycarbonyl)oxy)methoxy)phosphinyl)methoxy)propyl)adenine fumarate (1:1)
gs 4331-05
gsk-548470
bis(hydroxymethyl) (((r)-2-(6-amino-9h-purin-9-yl)-1-methylethoxy)methyl)phosphonate, bis(isopropyl carbonate) (ester), fumarate (1:1)
9-((r)-2-((bis(((isopropoxycarbonyl)oxy)methoxy)phosphinyl)methoxy)propyl)adenine, fumarate
D01982
tenofovir disoproxil fumarate (jan/usan)
202138-50-9
viread (tn)
[[(1r)-2-(6-aminopurin-9-yl)-1-methyl-ethoxy]methyl-(isopropoxycarbonyloxymethoxy)phosphoryl]oxymethyl isopropyl carbonate; fumaric acid
chebi:63718 ,
gsk548470
virea
tenofoviri disoproxili fumaras
CHEMBL1486
gs-4331-05-
pmpa-prodrug
tox21_113627
cas-202138-50-9
dtxsid5050426 ,
tox21_112532
dtxcid4029808
MLS004774141
smr003500786
HY-13782
tenofovir disoproxil (fumarate)
CS-1346
unii-ott9j7900i
ott9j7900i ,
BCP0726000258
9-((r)-2-((bis(((isopropoxycarbonyl)oxy)methoxy)phosphinyl)methoxy)propyl)adenine fumarate
bis({[(propan-2-yloxy)carbonyl]oxy}methyl) ({[(2r)-1-(6-amino-9h-purin-9-yl)propan-2-yl]oxy}methyl)phosphonate (2e)-but-2-enedioate
S1400
AKOS016340707
tenofovir disoproxil fumarate component of odefsey
tenofovir disoproxil fumarate [ema epar]
tenofoviri disoproxili fumaras [who-ip latin]
temixys component tenofovir disoproxil fumarate
bis(hydroxymethyl) [[(r)-2-(6-amino-9h-purin-9-yl)-1-methylethoxy]methyl]phosphonate, bis(isopropyl carbonate) (ester), fumarate (1:1)
stribild component tenofovir disoproxil fumarate
tenofovir disoproxil fumarate component of stribild
tenofovir disoproxil fumarate [mi]
tenofovir disoproxil fumarate component of truvada
tenofovir (as disoproxil fumarate)
tenofovir disoproxil fumarate component delstrigo
truvada component tenofovir disoproxil fumarate
tenofovir disoproxil fumarate [vandf]
atripla component tenofovir disoproxil fumarate
tenofovir disoproxil fumarate [who-ip]
tenofovir disoproxil fumarate component of temixys
delstrigo component tenofovir disoproxil fumarate
tenofovir disoproxil fumarate [who-dd]
tenofovir disoproxil fumarate [hsdb]
tenofovir disoproxil fumarate [usp-rs]
odefsey component tenofovir disoproxil fumarate
eviplera component tenofovir disoproxil fumarate
tenofovir disoproxil fumarate [jan]
tenofovir disoproxil fumarate [mart.]
tenofovir disoproxil fumarate [orange book]
9-((r)-2-((bis(((isopropoxycarbonyl)oxy)-methoxy)phosphinyl)methoxy)propyl)adenine fumarate (1:1)
tenofovir disoproxil fumarate component of atripla
tenofovir disoproxil fumarate component of eviplera
VCMJCVGFSROFHV-WZGZYPNHSA-N
AM20090676
2,4,6,8-tetraoxa-5-phosphanonanedioic acid, 5-[[(1r)-2-(6-amino-9h-purin-9-yl)-1-methylethoxy]methyl]-, 1,9-bis(1-methylethyl) ester, 5-oxide, (2e)-2-butenedioate (1:1)
SCHEMBL40021
tox21_113627_1
NCGC00183876-03
KS-1246
(r)-(((((1-(6-amino-9h-purin-9-yl)propan-2-yl)oxy)methyl)phosphoryl)bis(oxy))bis(methylene) diisopropyl dicarbonate fumarate
tenofovir-disoproxil-fumarate
tenofovirdisoproxilfumarate
SCHEMBL2670560
Q-201788
AKOS025149493
tenofovir (disoproxil fumarate)
EX-A590
gs-1278 disoproxil fumarate
tenofovir disoproxil fumarate, >=98% (hplc)
tenofovir disoproxil fumarate, pharmaceutical secondary standard; certified reference material
(2e)-but-2-enedioic acid bis({[(propan-2-yloxy)carbonyl]oxy}methyl) {[(2r)-1-(6-amino-9h-purin-9-yl)propan-2-yl]oxy}methanephosphonate
Q27132754
CCG-270300
(r)-(((((1-(6-amino-9h-purin-9-yl)propan-2-yl)oxy)methyl)phosphoryl)bis(oxy))bis(methylene)diisopropyldicarbonatefumarate
9-[(r)-2[[bis[[(isopropoxycarbonyl)oxy]methoxy]phosphinyl]methoxy]propyl]adenine fumarate (1:1)
tenofovir disoproxil fumarate- bio-x
BT164457
c23h34n5o14p

Research Excerpts

Dosage Studied

ExcerptRelevanceReference
" The pharmacokinetic profile of GS-9160 in healthy human volunteers revealed that once-daily dosing was not likely to achieve antiviral efficacy; hence, the clinical development of this compound was discontinued."( Preclinical evaluation of GS-9160, a novel inhibitor of human immunodeficiency virus type 1 integrase.
Chen, J; Chen, X; Geleziunas, R; Hesselgesser, J; Jin, H; Jones, GS; Kim, CU; Tsiang, M; Wright, M; Yu, F; Zeynalzadegan, A, 2009
)
0.35
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (3)

RoleDescription
prodrugA compound that, on administration, must undergo chemical conversion by metabolic processes before becoming the pharmacologically active drug for which it is a prodrug.
HIV-1 reverse transcriptase inhibitorAn entity which inhibits the activity of HIV-1 reverse transcriptase.
antiviral drugA substance used in the prophylaxis or therapy of virus diseases.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (1)

ClassDescription
fumarate saltAn organic salt derived from fumaric acid.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (11)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
TDP1 proteinHomo sapiens (human)Potency9.50370.000811.382244.6684AID686978; AID686979
AR proteinHomo sapiens (human)Potency10.59090.000221.22318,912.5098AID1259243
nuclear receptor subfamily 1, group I, member 3Homo sapiens (human)Potency1.96280.001022.650876.6163AID1224838; AID1224893
cytochrome P450 family 3 subfamily A polypeptide 4Homo sapiens (human)Potency6.91780.01237.983543.2770AID1645841
thyroid hormone receptor beta isoform 2Rattus norvegicus (Norway rat)Potency23.71010.000323.4451159.6830AID743065; AID743067
nuclear factor erythroid 2-related factor 2 isoform 1Homo sapiens (human)Potency11.88230.000627.21521,122.0200AID743202; AID743219
Spike glycoproteinSevere acute respiratory syndrome-related coronavirusPotency0.04290.009610.525035.4813AID1479148
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
ATP-binding cassette sub-family C member 3Homo sapiens (human)IC50 (µMol)133.00000.63154.45319.3000AID1473740
Multidrug resistance-associated protein 4Homo sapiens (human)IC50 (µMol)133.00000.20005.677410.0000AID1473741
Bile salt export pumpHomo sapiens (human)IC50 (µMol)133.00000.11007.190310.0000AID1473738
Canalicular multispecific organic anion transporter 1Homo sapiens (human)IC50 (µMol)133.00002.41006.343310.0000AID1473739
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (41)

Processvia Protein(s)Taxonomy
xenobiotic metabolic processATP-binding cassette sub-family C member 3Homo sapiens (human)
xenobiotic transmembrane transportATP-binding cassette sub-family C member 3Homo sapiens (human)
bile acid and bile salt transportATP-binding cassette sub-family C member 3Homo sapiens (human)
glucuronoside transportATP-binding cassette sub-family C member 3Homo sapiens (human)
xenobiotic transportATP-binding cassette sub-family C member 3Homo sapiens (human)
transmembrane transportATP-binding cassette sub-family C member 3Homo sapiens (human)
leukotriene transportATP-binding cassette sub-family C member 3Homo sapiens (human)
monoatomic anion transmembrane transportATP-binding cassette sub-family C member 3Homo sapiens (human)
transport across blood-brain barrierATP-binding cassette sub-family C member 3Homo sapiens (human)
prostaglandin secretionMultidrug resistance-associated protein 4Homo sapiens (human)
cilium assemblyMultidrug resistance-associated protein 4Homo sapiens (human)
platelet degranulationMultidrug resistance-associated protein 4Homo sapiens (human)
xenobiotic metabolic processMultidrug resistance-associated protein 4Homo sapiens (human)
xenobiotic transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
bile acid and bile salt transportMultidrug resistance-associated protein 4Homo sapiens (human)
prostaglandin transportMultidrug resistance-associated protein 4Homo sapiens (human)
urate transportMultidrug resistance-associated protein 4Homo sapiens (human)
glutathione transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
cAMP transportMultidrug resistance-associated protein 4Homo sapiens (human)
leukotriene transportMultidrug resistance-associated protein 4Homo sapiens (human)
monoatomic anion transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
export across plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
transport across blood-brain barrierMultidrug resistance-associated protein 4Homo sapiens (human)
guanine nucleotide transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
fatty acid metabolic processBile salt export pumpHomo sapiens (human)
bile acid biosynthetic processBile salt export pumpHomo sapiens (human)
xenobiotic metabolic processBile salt export pumpHomo sapiens (human)
xenobiotic transmembrane transportBile salt export pumpHomo sapiens (human)
response to oxidative stressBile salt export pumpHomo sapiens (human)
bile acid metabolic processBile salt export pumpHomo sapiens (human)
response to organic cyclic compoundBile salt export pumpHomo sapiens (human)
bile acid and bile salt transportBile salt export pumpHomo sapiens (human)
canalicular bile acid transportBile salt export pumpHomo sapiens (human)
protein ubiquitinationBile salt export pumpHomo sapiens (human)
regulation of fatty acid beta-oxidationBile salt export pumpHomo sapiens (human)
carbohydrate transmembrane transportBile salt export pumpHomo sapiens (human)
bile acid signaling pathwayBile salt export pumpHomo sapiens (human)
cholesterol homeostasisBile salt export pumpHomo sapiens (human)
response to estrogenBile salt export pumpHomo sapiens (human)
response to ethanolBile salt export pumpHomo sapiens (human)
xenobiotic export from cellBile salt export pumpHomo sapiens (human)
lipid homeostasisBile salt export pumpHomo sapiens (human)
phospholipid homeostasisBile salt export pumpHomo sapiens (human)
positive regulation of bile acid secretionBile salt export pumpHomo sapiens (human)
regulation of bile acid metabolic processBile salt export pumpHomo sapiens (human)
transmembrane transportBile salt export pumpHomo sapiens (human)
xenobiotic metabolic processCanalicular multispecific organic anion transporter 1Homo sapiens (human)
xenobiotic transmembrane transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
negative regulation of gene expressionCanalicular multispecific organic anion transporter 1Homo sapiens (human)
bile acid and bile salt transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
bilirubin transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
heme catabolic processCanalicular multispecific organic anion transporter 1Homo sapiens (human)
xenobiotic export from cellCanalicular multispecific organic anion transporter 1Homo sapiens (human)
transmembrane transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
transepithelial transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
leukotriene transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
monoatomic anion transmembrane transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
transport across blood-brain barrierCanalicular multispecific organic anion transporter 1Homo sapiens (human)
xenobiotic transport across blood-brain barrierCanalicular multispecific organic anion transporter 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (24)

Processvia Protein(s)Taxonomy
ATP bindingATP-binding cassette sub-family C member 3Homo sapiens (human)
ABC-type xenobiotic transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
glucuronoside transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ABC-type glutathione S-conjugate transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ABC-type bile acid transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ATP hydrolysis activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ATPase-coupled transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
xenobiotic transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ATPase-coupled inorganic anion transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
icosanoid transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ABC-type transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
guanine nucleotide transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
protein bindingMultidrug resistance-associated protein 4Homo sapiens (human)
ATP bindingMultidrug resistance-associated protein 4Homo sapiens (human)
ABC-type xenobiotic transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
prostaglandin transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
urate transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
purine nucleotide transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ABC-type glutathione S-conjugate transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ABC-type bile acid transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
efflux transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
15-hydroxyprostaglandin dehydrogenase (NAD+) activityMultidrug resistance-associated protein 4Homo sapiens (human)
ATP hydrolysis activityMultidrug resistance-associated protein 4Homo sapiens (human)
glutathione transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ATPase-coupled transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
xenobiotic transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ATPase-coupled inorganic anion transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ABC-type transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
protein bindingBile salt export pumpHomo sapiens (human)
ATP bindingBile salt export pumpHomo sapiens (human)
ABC-type xenobiotic transporter activityBile salt export pumpHomo sapiens (human)
bile acid transmembrane transporter activityBile salt export pumpHomo sapiens (human)
canalicular bile acid transmembrane transporter activityBile salt export pumpHomo sapiens (human)
carbohydrate transmembrane transporter activityBile salt export pumpHomo sapiens (human)
ABC-type bile acid transporter activityBile salt export pumpHomo sapiens (human)
ATP hydrolysis activityBile salt export pumpHomo sapiens (human)
protein bindingCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ATP bindingCanalicular multispecific organic anion transporter 1Homo sapiens (human)
organic anion transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ABC-type xenobiotic transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
bilirubin transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ABC-type glutathione S-conjugate transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ATP hydrolysis activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ATPase-coupled transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
xenobiotic transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ATPase-coupled inorganic anion transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ABC-type transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (18)

Processvia Protein(s)Taxonomy
plasma membraneATP-binding cassette sub-family C member 3Homo sapiens (human)
basal plasma membraneATP-binding cassette sub-family C member 3Homo sapiens (human)
basolateral plasma membraneATP-binding cassette sub-family C member 3Homo sapiens (human)
membraneATP-binding cassette sub-family C member 3Homo sapiens (human)
nucleolusMultidrug resistance-associated protein 4Homo sapiens (human)
Golgi apparatusMultidrug resistance-associated protein 4Homo sapiens (human)
plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
membraneMultidrug resistance-associated protein 4Homo sapiens (human)
basolateral plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
apical plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
platelet dense granule membraneMultidrug resistance-associated protein 4Homo sapiens (human)
external side of apical plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
basolateral plasma membraneBile salt export pumpHomo sapiens (human)
Golgi membraneBile salt export pumpHomo sapiens (human)
endosomeBile salt export pumpHomo sapiens (human)
plasma membraneBile salt export pumpHomo sapiens (human)
cell surfaceBile salt export pumpHomo sapiens (human)
apical plasma membraneBile salt export pumpHomo sapiens (human)
intercellular canaliculusBile salt export pumpHomo sapiens (human)
intracellular canaliculusBile salt export pumpHomo sapiens (human)
recycling endosomeBile salt export pumpHomo sapiens (human)
recycling endosome membraneBile salt export pumpHomo sapiens (human)
extracellular exosomeBile salt export pumpHomo sapiens (human)
membraneBile salt export pumpHomo sapiens (human)
virion membraneSpike glycoproteinSevere acute respiratory syndrome-related coronavirus
plasma membraneCanalicular multispecific organic anion transporter 1Homo sapiens (human)
cell surfaceCanalicular multispecific organic anion transporter 1Homo sapiens (human)
apical plasma membraneCanalicular multispecific organic anion transporter 1Homo sapiens (human)
intercellular canaliculusCanalicular multispecific organic anion transporter 1Homo sapiens (human)
apical plasma membraneCanalicular multispecific organic anion transporter 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (205)

Assay IDTitleYearJournalArticle
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1347100qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID1347105qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347103qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347102qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347090qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347091qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347095qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347099qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347107qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347093qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347096qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347101qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1347108qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347092qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347106qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347098qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347424RapidFire Mass Spectrometry qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347094qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347089qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347097qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347104qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347425Rhodamine-PBP qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347407qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Pharmaceutical Collection2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID541170Selectivity ratio of EC50 for antiviral activity against HIV1 harboring N155S mutation in catalytic core domain of integrase to EC50 for antiviral activity against wild-type HIV1 3B2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Preclinical evaluation of GS-9160, a novel inhibitor of human immunodeficiency virus type 1 integrase.
AID587757Ratio of EC50 for HIV1 NL4-3.Luc assessed as infectivity using human MDM pretreated for 24 hrs followed by exposed to virus after compound washout to standard EC50 for HIV1 NL4-3.Luc2011Antimicrobial agents and chemotherapy, Jan, Volume: 55, Issue:1
Identification and characterization of persistent intracellular human immunodeficiency virus type 1 integrase strand transfer inhibitor activity.
AID1473740Inhibition of human MRP3 overexpressed in Sf9 insect cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 10 mins by membrane vesicle transport assay2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID310044Antiviral activity against HIV1 3B in MT4 cells after 4 days by MTT assay2007Bioorganic & medicinal chemistry letters, Nov-15, Volume: 17, Issue:22
Some new acyclic nucleotide analogues as antiviral prodrugs: synthesis and bioactivities in vitro.
AID587754Antiviral activity against HIV1 NL4-3.Luc in human PBMC assessed as infectivity treated for 24 hrs by luciferase assay2011Antimicrobial agents and chemotherapy, Jan, Volume: 55, Issue:1
Identification and characterization of persistent intracellular human immunodeficiency virus type 1 integrase strand transfer inhibitor activity.
AID325086Drug level in human RBC assessed as concentration of tenofovir diphosphate per 10^6 cells after 14.3 hrs2007Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6
Evidence and possible consequences of the phosphorylation of nucleoside reverse transcriptase inhibitors in human red blood cells.
AID1599855Cytotoxicity against human HepG2.2.15 cells infected with HBV2019ACS medicinal chemistry letters, Jun-13, Volume: 10, Issue:6
Design, Synthesis, and Anti-HBV Activity of New Bis(l-amino acid) Ester Tenofovir Prodrugs.
AID587756Ratio of EC50 for HIV1 NL4-3.Luc assessed as infectivity using human PBMC pretreated for 24 hrs followed by exposed to virus after compound washout to standard EC50 for HIV1 NL4-3.Luc2011Antimicrobial agents and chemotherapy, Jan, Volume: 55, Issue:1
Identification and characterization of persistent intracellular human immunodeficiency virus type 1 integrase strand transfer inhibitor activity.
AID325101Drug level in RBC lysed human PBMC assessed as concentration of tenofovir diphosphate after 9.5 hrs2007Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6
Evidence and possible consequences of the phosphorylation of nucleoside reverse transcriptase inhibitors in human red blood cells.
AID1473739Inhibition of human MRP2 overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 20 mins by membrane vesicle transport assay2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID582428Toxicity in Woodchuck hepatitis virus infected woodchuck assessed as increase of serum gamma-glutamyltransferase activity at 15 mg/kg, po qd for 48 weeks2008Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10
Antiviral effects of lamivudine, emtricitabine, adefovir dipivoxil, and tenofovir disoproxil fumarate administered orally alone and in combination to woodchucks with chronic woodchuck hepatitis virus infection.
AID572769Antiviral activity against HIV1 infected in human PBMC assessed as inhibition of viral replication2009Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9
Anti-human immunodeficiency virus activity, cross-resistance, cytotoxicity, and intracellular pharmacology of the 3'-azido-2',3'-dideoxypurine nucleosides.
AID325099Drug level in non-lysed human PBMC assessed as concentration of tenofovir diphosphate after 9.5 hrs2007Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6
Evidence and possible consequences of the phosphorylation of nucleoside reverse transcriptase inhibitors in human red blood cells.
AID1599890Antiviral activity against HBV genotype D hydrodynamically infected as pHBV1.3 mer plasmid carrying viral genome in C57BL/6 mouse assessed as log10 reduction in serum viral DNA level at 0.10 to 0.50 mmol/kg/day, po via gavage administered as twice daily d2019ACS medicinal chemistry letters, Jun-13, Volume: 10, Issue:6
Design, Synthesis, and Anti-HBV Activity of New Bis(l-amino acid) Ester Tenofovir Prodrugs.
AID582403Antiviral activity against Woodchuck hepatitis virus infected in woodchuck assessed as reduction of viral antigen level in serum at 15 mg/kg, po qd for 48 weeks measured on 60th week (Rvb = 3.3 +/- 1.6 log10 ng/ml)2008Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10
Antiviral effects of lamivudine, emtricitabine, adefovir dipivoxil, and tenofovir disoproxil fumarate administered orally alone and in combination to woodchucks with chronic woodchuck hepatitis virus infection.
AID541165Selectivity ratio of EC50 for antiviral activity against HIV1 harboring E138K mutation in catalytic core domain of integrase to EC50 for antiviral activity against wild-type HIV1 3B2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Preclinical evaluation of GS-9160, a novel inhibitor of human immunodeficiency virus type 1 integrase.
AID1686652Antiviral activity against HIV1 infected in human PBMC assessed as reduction in viral replication incubated for 7 days by radioactive incorporation polymerization assay based reverse transcriptase activity detection method2016Journal of medicinal chemistry, 11-23, Volume: 59, Issue:22
Next-Generation Reduction Sensitive Lipid Conjugates of Tenofovir: Antiviral Activity and Mechanism of Release.
AID325094Ratio of drug level in human RBC to human PBMC assessed as concentration of Lamivudine triphosphate after 13.3 hrs2007Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6
Evidence and possible consequences of the phosphorylation of nucleoside reverse transcriptase inhibitors in human red blood cells.
AID582424Toxicity in Woodchuck hepatitis virus infected woodchuck assessed as effect on hematological parameters at 15 mg/kg, po qd for 48 weeks measured up to 60 weeks2008Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10
Antiviral effects of lamivudine, emtricitabine, adefovir dipivoxil, and tenofovir disoproxil fumarate administered orally alone and in combination to woodchucks with chronic woodchuck hepatitis virus infection.
AID549085Cytotoxicity against human ME180 cells after 24 hrs by XTT assay2010Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7
Development of hexadecyloxypropyl tenofovir (CMX157) for treatment of infection caused by wild-type and nucleoside/nucleotide-resistant HIV.
AID582401Antiviral activity against Woodchuck hepatitis virus infected in woodchuck assessed as reduction of viral antigen level in serum at 15 mg/kg, po qd measured on 36th week on 48 weeks study (Rvb = 3.8 +/- 1.3 log10 ng/ml)2008Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10
Antiviral effects of lamivudine, emtricitabine, adefovir dipivoxil, and tenofovir disoproxil fumarate administered orally alone and in combination to woodchucks with chronic woodchuck hepatitis virus infection.
AID587735Antiviral activity against HIV1 NL4-3.Luc assessed as infectivity using human PBMC pretreated for 24 hrs followed by exposed to virus after compound washout measured after 2 to 3 days by luciferase assay2011Antimicrobial agents and chemotherapy, Jan, Volume: 55, Issue:1
Identification and characterization of persistent intracellular human immunodeficiency virus type 1 integrase strand transfer inhibitor activity.
AID582397Antiviral activity against Woodchuck hepatitis virus infected in woodchuck assessed as frequency of hepatocytes expressing viral antigen at 15 mg/kg, po qd measured on 12th week on 48 weeks study2008Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10
Antiviral effects of lamivudine, emtricitabine, adefovir dipivoxil, and tenofovir disoproxil fumarate administered orally alone and in combination to woodchucks with chronic woodchuck hepatitis virus infection.
AID289141Inhibition of virus-induced cytopathic effect in wild type HIV 3a infected MT2 cells after 5 days2007Bioorganic & medicinal chemistry, Aug-15, Volume: 15, Issue:16
Synthesis, anti-HIV activity, and resistance profile of thymidine phosphonomethoxy nucleosides and their bis-isopropyloxymethylcarbonyl (bisPOC) prodrugs.
AID1782276Selectivity index, ratio of CC50 for human MT-4 cells to EC50 for HIV-1 infected in MT-4 cells2021Journal of medicinal chemistry, 11-25, Volume: 64, Issue:22
Discovery of Modified Amidate (ProTide) Prodrugs of Tenofovir with Enhanced Antiviral Properties.
AID541132Selectivity ratio of EC50 for antiviral activity against NNRTI-resistant HIV1 harboring RTK103N mutant gene to EC50 for antiviral activity against wild-type HIV1 3B2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Preclinical evaluation of GS-9160, a novel inhibitor of human immunodeficiency virus type 1 integrase.
AID1599881Antiviral activity against HBV infected in pekin duck assessed as reduction in serum viral DNA level administered via oral gavage twice daily for 14 days and measured on day 14 post treatment and on day 3 after treatment cessation by qRT-PCR analysis2019ACS medicinal chemistry letters, Jun-13, Volume: 10, Issue:6
Design, Synthesis, and Anti-HBV Activity of New Bis(l-amino acid) Ester Tenofovir Prodrugs.
AID582398Antiviral activity against Woodchuck hepatitis virus infected in woodchuck assessed as frequency of hepatocytes expressing viral antigen at 15 mg/kg, po qd for 48 weeks measured on 60th week2008Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10
Antiviral effects of lamivudine, emtricitabine, adefovir dipivoxil, and tenofovir disoproxil fumarate administered orally alone and in combination to woodchucks with chronic woodchuck hepatitis virus infection.
AID582420Antiviral activity against Woodchuck hepatitis virus infected in woodchuck assessed as absent of lesion in lobular hepatitis at 15 mg/kg, po qd measured on 36th week on 48 weeks study2008Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10
Antiviral effects of lamivudine, emtricitabine, adefovir dipivoxil, and tenofovir disoproxil fumarate administered orally alone and in combination to woodchucks with chronic woodchuck hepatitis virus infection.
AID582396Antiviral activity against Woodchuck hepatitis virus infected in woodchuck assessed as reduction of viral DNA replicative intermediate level per ug of total cell DNA at 15 mg/kg, po qd measured on 12th week on 48 weeks study (Rvb = 1495 +/- 890 pg)2008Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10
Antiviral effects of lamivudine, emtricitabine, adefovir dipivoxil, and tenofovir disoproxil fumarate administered orally alone and in combination to woodchucks with chronic woodchuck hepatitis virus infection.
AID582399Antiviral activity against Woodchuck hepatitis virus infected in woodchuck assessed as absent of lesion in portal hepatitis at 15 mg/kg, po qd measured on 12th week on 48 weeks study2008Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10
Antiviral effects of lamivudine, emtricitabine, adefovir dipivoxil, and tenofovir disoproxil fumarate administered orally alone and in combination to woodchucks with chronic woodchuck hepatitis virus infection.
AID1457760Cytotoxicity against human MT4 cells assessed as reduction in cell viability after 6 days by XTT tetrazolium dye-based assay2017Journal of medicinal chemistry, 07-27, Volume: 60, Issue:14
Expanding the Antiviral Spectrum of 3-Fluoro-2-(phosphonomethoxy)propyl Acyclic Nucleoside Phosphonates: Diamyl Aspartate Amidate Prodrugs.
AID1457751Antiviral activity against CXCR4-tropic HIV-1 NL4-3 infected in human PHA-stimulated PBMC assessed as inhibition of viral replication by measuring reduction in p24 antigen production preincubated with cells for 30 mins followed by viral infection measured2017Journal of medicinal chemistry, 07-27, Volume: 60, Issue:14
Expanding the Antiviral Spectrum of 3-Fluoro-2-(phosphonomethoxy)propyl Acyclic Nucleoside Phosphonates: Diamyl Aspartate Amidate Prodrugs.
AID310047Therapeutic index, Ratio of TC50 for human HepG2 cells to IC50 for HBV-infected human HepG2 cells2007Bioorganic & medicinal chemistry letters, Nov-15, Volume: 17, Issue:22
Some new acyclic nucleotide analogues as antiviral prodrugs: synthesis and bioactivities in vitro.
AID549084Cytotoxicity against human CEM-SS cells after 24 hrs by XTT assay2010Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7
Development of hexadecyloxypropyl tenofovir (CMX157) for treatment of infection caused by wild-type and nucleoside/nucleotide-resistant HIV.
AID1678115Antiviral activity against Hepatitis B virus infected in human HepG2.2.15 cells assessed as reduction in HBV DNA level in cell supernatants incubated for 5 days by real time PCR analysis2020Bioorganic & medicinal chemistry letters, 12-01, Volume: 30, Issue:23
Development of DHQ-based chemical biology probe to profile cellular targets for HBV.
AID1782294Antiviral activity against HIV-12021Journal of medicinal chemistry, 11-25, Volume: 64, Issue:22
Discovery of Modified Amidate (ProTide) Prodrugs of Tenofovir with Enhanced Antiviral Properties.
AID541163Selectivity ratio of EC50 for antiviral activity against HIV1 harboring E92Q mutation in catalytic core domain of integrase to EC50 for antiviral activity against wild-type HIV1 3B2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Preclinical evaluation of GS-9160, a novel inhibitor of human immunodeficiency virus type 1 integrase.
AID325102Ratio of drug level in non-lysed human PBMC to RBC lysed human PBMC assessed as concentration of tenofovir diphosphate after 2 hrs2007Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6
Evidence and possible consequences of the phosphorylation of nucleoside reverse transcriptase inhibitors in human red blood cells.
AID582430Toxicity in Woodchuck hepatitis virus infected woodchuck assessed as increase of liver aspartate aminotransferase activity at 15 mg/kg, po qd for 48 weeks2008Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10
Antiviral effects of lamivudine, emtricitabine, adefovir dipivoxil, and tenofovir disoproxil fumarate administered orally alone and in combination to woodchucks with chronic woodchuck hepatitis virus infection.
AID541172Selectivity ratio of EC50 for antiviral activity against HIV1 harboring E92V and V151A mutation in catalytic core domain of integrase to EC50 for antiviral activity against wild-type HIV1 3B2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Preclinical evaluation of GS-9160, a novel inhibitor of human immunodeficiency virus type 1 integrase.
AID541171Selectivity ratio of EC50 for antiviral activity against HIV1 harboring L74M and E92V mutation in catalytic core domain of integrase to EC50 for antiviral activity against wild-type HIV1 3B2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Preclinical evaluation of GS-9160, a novel inhibitor of human immunodeficiency virus type 1 integrase.
AID289144Antiviral activity against HIV1 with reverse transcriptase 6TAM mutation assessed as reduction of potency relative to wild type2007Bioorganic & medicinal chemistry, Aug-15, Volume: 15, Issue:16
Synthesis, anti-HIV activity, and resistance profile of thymidine phosphonomethoxy nucleosides and their bis-isopropyloxymethylcarbonyl (bisPOC) prodrugs.
AID1473741Inhibition of human MRP4 overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 20 mins by membrane vesicle transport assay2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID541174Selectivity ratio of EC50 for antiviral activity against HIV1 harboring E92V, G140S and V151A mutation in catalytic core domain of integrase to EC50 for antiviral activity against wild-type HIV1 3B2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Preclinical evaluation of GS-9160, a novel inhibitor of human immunodeficiency virus type 1 integrase.
AID582412Antiviral activity against Woodchuck hepatitis virus infected in woodchuck assessed as reduction of viral antigen positive hepatocytes at 15 mg/kg, po qd for 48 weeks study (Rvb = 35 +/- 27 %)2008Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10
Antiviral effects of lamivudine, emtricitabine, adefovir dipivoxil, and tenofovir disoproxil fumarate administered orally alone and in combination to woodchucks with chronic woodchuck hepatitis virus infection.
AID541164Selectivity ratio of EC50 for antiviral activity against HIV1 harboring E92V mutation in catalytic core domain of integrase to EC50 for antiviral activity against wild-type HIV1 3B2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Preclinical evaluation of GS-9160, a novel inhibitor of human immunodeficiency virus type 1 integrase.
AID1599884Toxicity against Pekin duck infected with HBV assessed as change in body weight at 0.1 to 0.4 mmol/kg, po twice daily for 14 days administered via gavage and measured every day during compound dosing2019ACS medicinal chemistry letters, Jun-13, Volume: 10, Issue:6
Design, Synthesis, and Anti-HBV Activity of New Bis(l-amino acid) Ester Tenofovir Prodrugs.
AID1599885Toxicity against C57BL/6 mouse hydrodynamically infected with pHBV1.3 mer plasmid carrying HBV genotype D assessed as change in body weight at 0.1 to 0.5 mmol/kg/day, po via gavage administered as twice daily dosage and measured upto 6 days post treatment2019ACS medicinal chemistry letters, Jun-13, Volume: 10, Issue:6
Design, Synthesis, and Anti-HBV Activity of New Bis(l-amino acid) Ester Tenofovir Prodrugs.
AID549089Cytotoxicity against human bone marrow cells after 24 hrs by BFU-E assay2010Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7
Development of hexadecyloxypropyl tenofovir (CMX157) for treatment of infection caused by wild-type and nucleoside/nucleotide-resistant HIV.
AID582427Toxicity in Woodchuck hepatitis virus infected woodchuck assessed as increase of liver sorbitol dehydrogenase activity at 15 mg/kg, po qd measured on 28 to 48 weeks on 48 week study2008Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10
Antiviral effects of lamivudine, emtricitabine, adefovir dipivoxil, and tenofovir disoproxil fumarate administered orally alone and in combination to woodchucks with chronic woodchuck hepatitis virus infection.
AID541168Selectivity ratio of EC50 for antiviral activity against HIV1 harboring V151A mutation in catalytic core domain of integrase to EC50 for antiviral activity against wild-type HIV1 3B2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Preclinical evaluation of GS-9160, a novel inhibitor of human immunodeficiency virus type 1 integrase.
AID416856Ratio of permeability from basolateral to apical side over apical to basolateral side in human Caco-2 cells at 1000 uM2007Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10
Effects of human immunodeficiency virus protease inhibitors on the intestinal absorption of tenofovir disoproxil fumarate in vitro.
AID549087Cytotoxicity against human HepG2 cells after 24 hrs by XTT assay2010Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7
Development of hexadecyloxypropyl tenofovir (CMX157) for treatment of infection caused by wild-type and nucleoside/nucleotide-resistant HIV.
AID1636527Antiviral activity against HBV infected in human HepG2.2.15 cells assessed as inhibition of viral DNA in cell supernatant incubated for 3 days in presence of 10% FBS followed by compound treatment in absence of 10% FBS for 3 days by qRT-PCR method2016Journal of medicinal chemistry, 08-11, Volume: 59, Issue:15
Reduction Sensitive Lipid Conjugates of Tenofovir: Synthesis, Stability, and Antiviral Activity.
AID369218Antiviral activity against woodchuck hepatitis virus infected woodchucks assessed as log reduction of serum viral DNA per ml of serum after 4 weeks2007Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9
Antiviral effect of orally administered (-)-beta-D-2-aminopurine dioxolane in woodchucks with chronic woodchuck hepatitis virus infection.
AID582425Toxicity in Woodchuck hepatitis virus infected woodchuck assessed as increase of liver sorbitol dehydrogenase activity at 15 mg/kg, po qd measured on 4 to 24 weeks on 48 week study2008Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10
Antiviral effects of lamivudine, emtricitabine, adefovir dipivoxil, and tenofovir disoproxil fumarate administered orally alone and in combination to woodchucks with chronic woodchuck hepatitis virus infection.
AID1457788Antiviral activity against CXCR4-tropic HIV-1 NL4-3 infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect after 6 days by XTT dye based assay2017Journal of medicinal chemistry, 07-27, Volume: 60, Issue:14
Expanding the Antiviral Spectrum of 3-Fluoro-2-(phosphonomethoxy)propyl Acyclic Nucleoside Phosphonates: Diamyl Aspartate Amidate Prodrugs.
AID582419Antiviral activity against Woodchuck hepatitis virus infected in woodchuck assessed as absent of lesion in lobular hepatitis at 15 mg/kg, po qd measured on 12th week on 48 weeks study2008Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10
Antiviral effects of lamivudine, emtricitabine, adefovir dipivoxil, and tenofovir disoproxil fumarate administered orally alone and in combination to woodchucks with chronic woodchuck hepatitis virus infection.
AID582408Antiviral activity against Woodchuck hepatitis virus infected in woodchuck assessed as reduction of viral RNA level per ug of total cell DNA at 15 mg/kg, po qd for 48 weeks (Rvb = 34 +/- 20 pg)2008Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10
Antiviral effects of lamivudine, emtricitabine, adefovir dipivoxil, and tenofovir disoproxil fumarate administered orally alone and in combination to woodchucks with chronic woodchuck hepatitis virus infection.
AID1457752Antiviral activity against CCR5 tropic HIV1 BaL infected in human PHA-stimulated PBMC assessed as inhibition of viral replication by measuring reduction in p24 antigen production preincubated with cells for 30 mins followed by viral infection measured on 2017Journal of medicinal chemistry, 07-27, Volume: 60, Issue:14
Expanding the Antiviral Spectrum of 3-Fluoro-2-(phosphonomethoxy)propyl Acyclic Nucleoside Phosphonates: Diamyl Aspartate Amidate Prodrugs.
AID582418Antiviral activity against Woodchuck hepatitis virus infected in woodchuck assessed as absent of lesion in portal hepatitis at 15 mg/kg, po qd for 48 weeks measured on 60th week2008Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10
Antiviral effects of lamivudine, emtricitabine, adefovir dipivoxil, and tenofovir disoproxil fumarate administered orally alone and in combination to woodchucks with chronic woodchuck hepatitis virus infection.
AID587746Antiviral activity against single-round HIV1 NLX.Lux-R harboring inactivating mutations in env, vpr and carries firefly luciferase gene in place of nef assessed as level of infection using human HeLaT4 cells pretreated at 100 time EC95 for 24 hrs followed2011Antimicrobial agents and chemotherapy, Jan, Volume: 55, Issue:1
Identification and characterization of persistent intracellular human immunodeficiency virus type 1 integrase strand transfer inhibitor activity.
AID541109Antiviral activity against HIV1 3B infected in human MT-2 cells by two fold dilution method in presence of 10% FBS2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Preclinical evaluation of GS-9160, a novel inhibitor of human immunodeficiency virus type 1 integrase.
AID549086Cytotoxicity against human HuH7 cells after 24 hrs by XTT assay2010Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7
Development of hexadecyloxypropyl tenofovir (CMX157) for treatment of infection caused by wild-type and nucleoside/nucleotide-resistant HIV.
AID1599872Oral bioavailability in Sprague-Dawley rat at 44.3 mg/kg administered as single dose and measured after 0.25 to 24 hrs by HPLC analysis2019ACS medicinal chemistry letters, Jun-13, Volume: 10, Issue:6
Design, Synthesis, and Anti-HBV Activity of New Bis(l-amino acid) Ester Tenofovir Prodrugs.
AID325103Ratio of drug level in non-lysed human PBMC to RBC lysed human PBMC assessed as concentration of tenofovir diphosphate after 9.5 hrs2007Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6
Evidence and possible consequences of the phosphorylation of nucleoside reverse transcriptase inhibitors in human red blood cells.
AID1473738Inhibition of human BSEP overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-taurocholate in presence of ATP measured after 15 to 20 mins by membrane vesicle transport assay2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID416861Inhibition of esterase mediated-hydrolysis of tenofovir disoproxil fumarate in human intestinal sub cellular fraction S9 assessed as rate of tenofovir disoproxil fumarate degradation at 10 uM after 30 mins2007Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10
Effects of human immunodeficiency virus protease inhibitors on the intestinal absorption of tenofovir disoproxil fumarate in vitro.
AID325088Drug level in human PBMC assessed as concentration of tenofovir diphosphate per 10^6 cells after 11.9 hrs2007Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6
Evidence and possible consequences of the phosphorylation of nucleoside reverse transcriptase inhibitors in human red blood cells.
AID1686653Cytotoxicity in uninfected human PBMC assessed as reduction in cell viability by XTT assay2016Journal of medicinal chemistry, 11-23, Volume: 59, Issue:22
Next-Generation Reduction Sensitive Lipid Conjugates of Tenofovir: Antiviral Activity and Mechanism of Release.
AID325087Drug level in human RBC assessed as concentration of tenofovir diphosphate per 10^6 cells after 13.5 hrs2007Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6
Evidence and possible consequences of the phosphorylation of nucleoside reverse transcriptase inhibitors in human red blood cells.
AID1636528Cytotoxicity against human HepG2.2.15 cells assessed as reduction in cell viability after 6 days by XTT assay2016Journal of medicinal chemistry, 08-11, Volume: 59, Issue:15
Reduction Sensitive Lipid Conjugates of Tenofovir: Synthesis, Stability, and Antiviral Activity.
AID289145Antiviral activity against HIV1 with reverse transcriptase K65R mutation assessed as reduction of potency relative to wild type2007Bioorganic & medicinal chemistry, Aug-15, Volume: 15, Issue:16
Synthesis, anti-HIV activity, and resistance profile of thymidine phosphonomethoxy nucleosides and their bis-isopropyloxymethylcarbonyl (bisPOC) prodrugs.
AID582411Antiviral activity against Woodchuck hepatitis virus infected in woodchuck assessed as reduction of viral antigen positive hepatocytes at 15 mg/kg, po qd measured on 36th week on 48 weeks study (Rvb = 41 +/- 25 %)2008Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10
Antiviral effects of lamivudine, emtricitabine, adefovir dipivoxil, and tenofovir disoproxil fumarate administered orally alone and in combination to woodchucks with chronic woodchuck hepatitis virus infection.
AID1636530Therapeutic index, ratio of CC90 for human PBMC to EC90 for HIV1 infected in human PBMC2016Journal of medicinal chemistry, 08-11, Volume: 59, Issue:15
Reduction Sensitive Lipid Conjugates of Tenofovir: Synthesis, Stability, and Antiviral Activity.
AID541134Selectivity ratio of EC50 for antiviral activity against PI-resistant HIV1 harboring RTI84V, L90M mutant gene to EC50 for antiviral activity against wild-type HIV1 3B2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Preclinical evaluation of GS-9160, a novel inhibitor of human immunodeficiency virus type 1 integrase.
AID582410Antiviral activity against Woodchuck hepatitis virus infected in woodchuck assessed as reduction of viral antigen positive hepatocytes at 15 mg/kg, po qd measured on 12th week on 48 weeks study (Rvb = 55 +/- 32 %)2008Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10
Antiviral effects of lamivudine, emtricitabine, adefovir dipivoxil, and tenofovir disoproxil fumarate administered orally alone and in combination to woodchucks with chronic woodchuck hepatitis virus infection.
AID1599870Cmax in Sprague-Dawley rat at 44.3 mg/kg, po administered as single dose and measured after 0.25 to 24 hrs by HPLC analysis2019ACS medicinal chemistry letters, Jun-13, Volume: 10, Issue:6
Design, Synthesis, and Anti-HBV Activity of New Bis(l-amino acid) Ester Tenofovir Prodrugs.
AID1636529Therapeutic index, ratio of CC50 for human HepG2.2.15 cells to EC50 for HBV infected in human HepG2.2.15 cells2016Journal of medicinal chemistry, 08-11, Volume: 59, Issue:15
Reduction Sensitive Lipid Conjugates of Tenofovir: Synthesis, Stability, and Antiviral Activity.
AID587748Ratio of EC50 for single-round HIV1 NLX.Lux-R harboring inactivating mutations in env, vpr and carries firefly luciferase gene in place of nef assessed as level of infection using human HeLaT4 cells pretreated for 24 hrs followed by exposed to virus immed2011Antimicrobial agents and chemotherapy, Jan, Volume: 55, Issue:1
Identification and characterization of persistent intracellular human immunodeficiency virus type 1 integrase strand transfer inhibitor activity.
AID325083Drug level in human RBC assessed as concentration of tenofovir diphosphate per 10^6 cells after 11.9 hrs2007Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6
Evidence and possible consequences of the phosphorylation of nucleoside reverse transcriptase inhibitors in human red blood cells.
AID1599856Antiviral activity against HBV infected in human HepG2.2.15 cells assessed as reduction in cytoplasmic DNA synthesis by reed and munch method2019ACS medicinal chemistry letters, Jun-13, Volume: 10, Issue:6
Design, Synthesis, and Anti-HBV Activity of New Bis(l-amino acid) Ester Tenofovir Prodrugs.
AID325091Drug level in human PBMC assessed as concentration of tenofovir diphosphate per 10^6 cells after 14.3 hrs2007Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6
Evidence and possible consequences of the phosphorylation of nucleoside reverse transcriptase inhibitors in human red blood cells.
AID582429Toxicity in Woodchuck hepatitis virus infected woodchuck assessed as increase of liver alanine aminotransferase activity at 15 mg/kg, po qd for 48 weeks2008Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10
Antiviral effects of lamivudine, emtricitabine, adefovir dipivoxil, and tenofovir disoproxil fumarate administered orally alone and in combination to woodchucks with chronic woodchuck hepatitis virus infection.
AID1599868Half-life in Sprague-Dawley rat at 44.3 mg/kg, po administered as single dose and measured after 0.25 to 24 hrs by HPLC analysis2019ACS medicinal chemistry letters, Jun-13, Volume: 10, Issue:6
Design, Synthesis, and Anti-HBV Activity of New Bis(l-amino acid) Ester Tenofovir Prodrugs.
AID1457759Selectivity ratio of EC50 for tenofovir-resistant CXCR4-tropic HIV-1 NL4-3 harboring reverse transcriptase K65R mutant infected in human MT4 cells to EC50 for CXCR4-tropic HIV-1 NL4-3 infected in human MT4 cells2017Journal of medicinal chemistry, 07-27, Volume: 60, Issue:14
Expanding the Antiviral Spectrum of 3-Fluoro-2-(phosphonomethoxy)propyl Acyclic Nucleoside Phosphonates: Diamyl Aspartate Amidate Prodrugs.
AID1599869Tmax in Sprague-Dawley rat at 44.3 mg/kg, po administered as single dose and measured after 0.25 to 24 hrs by HPLC analysis2019ACS medicinal chemistry letters, Jun-13, Volume: 10, Issue:6
Design, Synthesis, and Anti-HBV Activity of New Bis(l-amino acid) Ester Tenofovir Prodrugs.
AID416862Inhibition of esterase mediated-hydrolysis of tenofovir disoproxil fumarate in human intestinal sub cellular fraction S9 assessed as rate of tenofovir disoproxil fumarate degradation at 50 uM after 30 mins2007Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10
Effects of human immunodeficiency virus protease inhibitors on the intestinal absorption of tenofovir disoproxil fumarate in vitro.
AID549088Cytotoxicity against human bone marrow cells after 24 hrs by GM-CFU assay2010Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7
Development of hexadecyloxypropyl tenofovir (CMX157) for treatment of infection caused by wild-type and nucleoside/nucleotide-resistant HIV.
AID582416Antiviral activity against Woodchuck hepatitis virus infected in woodchuck assessed as absent of lesion in portal hepatitis at 15 mg/kg, po qd measured on 36th week on 48 weeks study2008Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10
Antiviral effects of lamivudine, emtricitabine, adefovir dipivoxil, and tenofovir disoproxil fumarate administered orally alone and in combination to woodchucks with chronic woodchuck hepatitis virus infection.
AID582400Antiviral activity against Woodchuck hepatitis virus infected in woodchuck assessed as reduction of viral antigen level in serum at 15 mg/kg, po qd measured on 12th week on 48 weeks study (Rvb = 4.3 +/- 1.5 log10 ng/ml)2008Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10
Antiviral effects of lamivudine, emtricitabine, adefovir dipivoxil, and tenofovir disoproxil fumarate administered orally alone and in combination to woodchucks with chronic woodchuck hepatitis virus infection.
AID416858Increase in P-glycoprotein-mediated forward permeation of tenofovir disoproxil fumarate in human Caco-2 cells at 10 uM2007Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10
Effects of human immunodeficiency virus protease inhibitors on the intestinal absorption of tenofovir disoproxil fumarate in vitro.
AID1457756Selectivity index, ratio of CC50 for human PHA-stimulated PBMC to IC50 for CXCR4-tropic HIV-1 NL4-3 infected in human PHA-stimulated PBMC2017Journal of medicinal chemistry, 07-27, Volume: 60, Issue:14
Expanding the Antiviral Spectrum of 3-Fluoro-2-(phosphonomethoxy)propyl Acyclic Nucleoside Phosphonates: Diamyl Aspartate Amidate Prodrugs.
AID541133Selectivity ratio of EC50 for antiviral activity against NNRTI-resistant HIV1 harboring RTY181C mutant gene to EC50 for antiviral activity against wild-type HIV1 3B2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Preclinical evaluation of GS-9160, a novel inhibitor of human immunodeficiency virus type 1 integrase.
AID1599871AUC(0 to infinity) in Sprague-Dawley rat at 44.3 mg/kg, po administered as single dose and measured after 0.25 to 24 hrs by HPLC analysis2019ACS medicinal chemistry letters, Jun-13, Volume: 10, Issue:6
Design, Synthesis, and Anti-HBV Activity of New Bis(l-amino acid) Ester Tenofovir Prodrugs.
AID325092Drug level in human PBMC assessed as concentration of tenofovir diphosphate per 10^6 cells after 13.5 hrs2007Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6
Evidence and possible consequences of the phosphorylation of nucleoside reverse transcriptase inhibitors in human red blood cells.
AID582431Toxicity in Woodchuck hepatitis virus infected woodchuck assessed as increase of liver alkaline phosphatase activity at 15 mg/kg, po qd for 48 weeks2008Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10
Antiviral effects of lamivudine, emtricitabine, adefovir dipivoxil, and tenofovir disoproxil fumarate administered orally alone and in combination to woodchucks with chronic woodchuck hepatitis virus infection.
AID582405Antiviral activity against Woodchuck hepatitis virus infected in woodchuck assessed as reduction of viral DNA replicative intermediate level per ug of total cell DNA at 15 mg/kg, po qd for 48 weeks measured on 60th week (Rvb = 979 pg)2008Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10
Antiviral effects of lamivudine, emtricitabine, adefovir dipivoxil, and tenofovir disoproxil fumarate administered orally alone and in combination to woodchucks with chronic woodchuck hepatitis virus infection.
AID582409Antiviral activity against Woodchuck hepatitis virus infected in woodchuck assessed as reduction of viral RNA level per ug of total cell DNA at 15 mg/kg, po qd for 48 weeks measured on 60th week (Rvb = 27 pg)2008Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10
Antiviral effects of lamivudine, emtricitabine, adefovir dipivoxil, and tenofovir disoproxil fumarate administered orally alone and in combination to woodchucks with chronic woodchuck hepatitis virus infection.
AID289143Cytotoxicity against MT2 cells2007Bioorganic & medicinal chemistry, Aug-15, Volume: 15, Issue:16
Synthesis, anti-HIV activity, and resistance profile of thymidine phosphonomethoxy nucleosides and their bis-isopropyloxymethylcarbonyl (bisPOC) prodrugs.
AID549081Cytotoxicity against human dendritic cells after 24 hrs by XTT assay2010Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7
Development of hexadecyloxypropyl tenofovir (CMX157) for treatment of infection caused by wild-type and nucleoside/nucleotide-resistant HIV.
AID587753Antiviral activity against single-round HIV1 NLX.Lux-R harboring inactivating mutations in env, vpr and carries firefly luciferase gene in place of nef assessed as level of 2 mins magnetic nanopartials-medated infection in human HeLaT4 cells treated for 12011Antimicrobial agents and chemotherapy, Jan, Volume: 55, Issue:1
Identification and characterization of persistent intracellular human immunodeficiency virus type 1 integrase strand transfer inhibitor activity.
AID587738Antiviral activity against single-round HIV1 NLX.Lux-R harboring inactivating mutations in env, vpr and carries firefly luciferase gene in place of nef infected in human HeLa-T4 cells assessed as luciferase activity after 48 hrs by exogenous RT assay2011Antimicrobial agents and chemotherapy, Jan, Volume: 55, Issue:1
Identification and characterization of persistent intracellular human immunodeficiency virus type 1 integrase strand transfer inhibitor activity.
AID416854Apparent permeability across human Caco-2 cells assessed as efflux saturation binding constant2007Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10
Effects of human immunodeficiency virus protease inhibitors on the intestinal absorption of tenofovir disoproxil fumarate in vitro.
AID1599882Antiviral activity against HBV infected in pekin duck assessed as log10 reduction in serum viral DNA level at 0.1 to 0.4 mmol/kg, po via gavage twice daily for 14 days and measured on day 14 post treatment and and on day 3 after treatment cessation by qRT2019ACS medicinal chemistry letters, Jun-13, Volume: 10, Issue:6
Design, Synthesis, and Anti-HBV Activity of New Bis(l-amino acid) Ester Tenofovir Prodrugs.
AID1636525Cytotoxicity against human PBMC assessed as reduction in cell viability by XTT assay2016Journal of medicinal chemistry, 08-11, Volume: 59, Issue:15
Reduction Sensitive Lipid Conjugates of Tenofovir: Synthesis, Stability, and Antiviral Activity.
AID582407Antiviral activity against Woodchuck hepatitis virus infected in woodchuck assessed as reduction of viral RNA level per ug of total cell DNA at 15 mg/kg, po qd measured on 36th week on 48 weeks study (Rvb = 33 +/- 21 pg)2008Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10
Antiviral effects of lamivudine, emtricitabine, adefovir dipivoxil, and tenofovir disoproxil fumarate administered orally alone and in combination to woodchucks with chronic woodchuck hepatitis virus infection.
AID541167Selectivity ratio of EC50 for antiviral activity against HIV1 harboring Q148K mutation in catalytic core domain of integrase to EC50 for antiviral activity against wild-type HIV1 3B2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Preclinical evaluation of GS-9160, a novel inhibitor of human immunodeficiency virus type 1 integrase.
AID572777Antiviral activity against HIV1 harboring reverse transcriptase Q151M mutant infected in human HeLa P4/R5 cells assessed as inhibition of viral replication2009Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9
Anti-human immunodeficiency virus activity, cross-resistance, cytotoxicity, and intracellular pharmacology of the 3'-azido-2',3'-dideoxypurine nucleosides.
AID582406Antiviral activity against Woodchuck hepatitis virus infected in woodchuck assessed as reduction of viral RNA level per ug of total cell DNA at 15 mg/kg, po qd measured on 12th week on 48 weeks study (Rvb = 46 +/- 25 pg)2008Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10
Antiviral effects of lamivudine, emtricitabine, adefovir dipivoxil, and tenofovir disoproxil fumarate administered orally alone and in combination to woodchucks with chronic woodchuck hepatitis virus infection.
AID325089Drug level in human PBMC assessed as concentration of tenofovir diphosphate per 10^6 cells after 13.9 hrs2007Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6
Evidence and possible consequences of the phosphorylation of nucleoside reverse transcriptase inhibitors in human red blood cells.
AID572778Ratio of IC50 for HIV1 harboring reverse transcriptase K65R mutant infected in human HeLa P4/R5 cells to wild type HIV1 infected in human HeLa P4/R5 cells2009Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9
Anti-human immunodeficiency virus activity, cross-resistance, cytotoxicity, and intracellular pharmacology of the 3'-azido-2',3'-dideoxypurine nucleosides.
AID541130Selectivity ratio of EC50 for antiviral activity against NRTI-resistant HIV1 harboring RTM184V mutant gene to EC50 for antiviral activity against wild-type HIV1 3B2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Preclinical evaluation of GS-9160, a novel inhibitor of human immunodeficiency virus type 1 integrase.
AID582413Antiviral activity against Woodchuck hepatitis virus infected in woodchuck assessed as reduction of viral antigen positive hepatocytes at 15 mg/kg, po qd for 48 weeks measured on 60th week (Rvb = 26 %)2008Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10
Antiviral effects of lamivudine, emtricitabine, adefovir dipivoxil, and tenofovir disoproxil fumarate administered orally alone and in combination to woodchucks with chronic woodchuck hepatitis virus infection.
AID325093Ratio of drug level in human RBC to human PBMC assessed as concentration of Lamivudine triphosphate after 11.9 hrs2007Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6
Evidence and possible consequences of the phosphorylation of nucleoside reverse transcriptase inhibitors in human red blood cells.
AID541169Selectivity ratio of EC50 for antiviral activity against HIV1 harboring N155H mutation in catalytic core domain of integrase to EC50 for antiviral activity against wild-type HIV1 3B2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Preclinical evaluation of GS-9160, a novel inhibitor of human immunodeficiency virus type 1 integrase.
AID416855Ratio of permeability from basolateral to apical side over apical to basolateral side in human Caco-2 cells at 1 uM2007Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10
Effects of human immunodeficiency virus protease inhibitors on the intestinal absorption of tenofovir disoproxil fumarate in vitro.
AID1599888Antiviral activity against HBV genotype D hydrodynamically infected as pHBV1.3 mer plasmid carrying viral genome in C57BL/6 mouse assessed as reduction in serum viral DNA level at 0.10 to 0.50 mmol/kg/day, po via gavage administered as twice daily dosage 2019ACS medicinal chemistry letters, Jun-13, Volume: 10, Issue:6
Design, Synthesis, and Anti-HBV Activity of New Bis(l-amino acid) Ester Tenofovir Prodrugs.
AID582395Antiviral activity against Woodchuck hepatitis virus infected in woodchuck assessed as reduction of viral DNA replicative intermediate level per ug of total cell DNA at 15 mg/kg, po qd measured on 36th week on 48 weeks study (Rvb = 1132 +/- 738 pg)2008Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10
Antiviral effects of lamivudine, emtricitabine, adefovir dipivoxil, and tenofovir disoproxil fumarate administered orally alone and in combination to woodchucks with chronic woodchuck hepatitis virus infection.
AID572780Ratio of IC50 for HIV1 harboring reverse transcriptase M184V mutant infected in human HeLa P4/R5 cells to wild type HIV1 infected in human HeLa P4/R5 cells2009Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9
Anti-human immunodeficiency virus activity, cross-resistance, cytotoxicity, and intracellular pharmacology of the 3'-azido-2',3'-dideoxypurine nucleosides.
AID310045Cytotoxicity against human HepG2 cells after 9 days by MTT assay2007Bioorganic & medicinal chemistry letters, Nov-15, Volume: 17, Issue:22
Some new acyclic nucleotide analogues as antiviral prodrugs: synthesis and bioactivities in vitro.
AID541175Selectivity ratio of EC50 for antiviral activity against HIV1 harboring G140S and Q148H mutation in catalytic core domain of integrase to EC50 for antiviral activity against wild-type HIV1 3B2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Preclinical evaluation of GS-9160, a novel inhibitor of human immunodeficiency virus type 1 integrase.
AID1457753Cytotoxicity against human PHA-stimulated PBMC assessed as cell viability by tetrazolium dye assay2017Journal of medicinal chemistry, 07-27, Volume: 60, Issue:14
Expanding the Antiviral Spectrum of 3-Fluoro-2-(phosphonomethoxy)propyl Acyclic Nucleoside Phosphonates: Diamyl Aspartate Amidate Prodrugs.
AID582426Toxicity in Woodchuck hepatitis virus infected woodchuck assessed as increase of liver alanine aminotransferase activity at 15 mg/kg, po qd measured on 4 to 24 weeks on 48 week study2008Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10
Antiviral effects of lamivudine, emtricitabine, adefovir dipivoxil, and tenofovir disoproxil fumarate administered orally alone and in combination to woodchucks with chronic woodchuck hepatitis virus infection.
AID1457757Selectivity index, ratio of CC50 for human PHA-stimulated PBMCs to IC50 for CCR5 tropic HIV1 BaL infected in human PHA-stimulated PBMC2017Journal of medicinal chemistry, 07-27, Volume: 60, Issue:14
Expanding the Antiviral Spectrum of 3-Fluoro-2-(phosphonomethoxy)propyl Acyclic Nucleoside Phosphonates: Diamyl Aspartate Amidate Prodrugs.
AID582414Antiviral activity against Woodchuck hepatitis virus infected in woodchuck assessed as frequency of hepatocytes expressing viral antigen at 15 mg/kg, po qd measured on 36th week on 48 weeks study2008Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10
Antiviral effects of lamivudine, emtricitabine, adefovir dipivoxil, and tenofovir disoproxil fumarate administered orally alone and in combination to woodchucks with chronic woodchuck hepatitis virus infection.
AID310043Antiviral activity against Hepatitis B virus infected human HepG2 cells after 9 days by MTT assay2007Bioorganic & medicinal chemistry letters, Nov-15, Volume: 17, Issue:22
Some new acyclic nucleotide analogues as antiviral prodrugs: synthesis and bioactivities in vitro.
AID1678116Antiviral activity against Hepatitis B virus infected in human HepG2.2.15 cells assessed as reduction in HBsAg level in cell supernatants incubated for 5 days by AlphaLisa assay2020Bioorganic & medicinal chemistry letters, 12-01, Volume: 30, Issue:23
Development of DHQ-based chemical biology probe to profile cellular targets for HBV.
AID1686655Antiviral activity against HBV infected in human HepG2 assessed as reduction in viral replication incubated for 6 days by real time Q-PCR analysis2016Journal of medicinal chemistry, 11-23, Volume: 59, Issue:22
Next-Generation Reduction Sensitive Lipid Conjugates of Tenofovir: Antiviral Activity and Mechanism of Release.
AID325098Drug level in non-lysed human PBMC assessed as concentration of tenofovir diphosphate after 2 hrs2007Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6
Evidence and possible consequences of the phosphorylation of nucleoside reverse transcriptase inhibitors in human red blood cells.
AID541162Selectivity ratio of EC50 for antiviral activity against HIV1 harboring L74M mutation in catalytic core domain of integrase to EC50 for antiviral activity against wild-type HIV1 3B2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Preclinical evaluation of GS-9160, a novel inhibitor of human immunodeficiency virus type 1 integrase.
AID587740Selectivity index, ratio of CC50 for human HeLa-T4 cells to EC50 for single-round HIV1 NLX.Lux-R harboring inactivating mutations in env, vpr and carries firefly luciferase gene in place of nef2011Antimicrobial agents and chemotherapy, Jan, Volume: 55, Issue:1
Identification and characterization of persistent intracellular human immunodeficiency virus type 1 integrase strand transfer inhibitor activity.
AID416860Increase in P-glycoprotein-mediated forward permeation of tenofovir disoproxil fumarate in human Caco-2 cells at 2 uM2007Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10
Effects of human immunodeficiency virus protease inhibitors on the intestinal absorption of tenofovir disoproxil fumarate in vitro.
AID587742Drug uptake in human HeLaT4 cells assessed as compound persist measured after 3 times washout at 100 time EC95 for HIV1 for 24 hrs2011Antimicrobial agents and chemotherapy, Jan, Volume: 55, Issue:1
Identification and characterization of persistent intracellular human immunodeficiency virus type 1 integrase strand transfer inhibitor activity.
AID541166Selectivity ratio of EC50 for antiviral activity against HIV1 harboring G140S mutation in catalytic core domain of integrase to EC50 for antiviral activity against wild-type HIV1 3B2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Preclinical evaluation of GS-9160, a novel inhibitor of human immunodeficiency virus type 1 integrase.
AID325096Ratio of drug level in human RBC to human PBMC assessed as concentration of Lamivudine triphosphate after 14.3 hrs2007Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6
Evidence and possible consequences of the phosphorylation of nucleoside reverse transcriptase inhibitors in human red blood cells.
AID325100Drug level in RBC lysed human PBMC assessed as concentration of tenofovir diphosphate after 2 hrs2007Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6
Evidence and possible consequences of the phosphorylation of nucleoside reverse transcriptase inhibitors in human red blood cells.
AID416863Inhibition of esterase mediated-hydrolysis of tenofovir disoproxil fumarate in human intestinal sub cellular fraction S9 assessed as rate of tenofovir disoproxil fumarate degradation at 100 uM after 30 mins2007Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10
Effects of human immunodeficiency virus protease inhibitors on the intestinal absorption of tenofovir disoproxil fumarate in vitro.
AID549082Cytotoxicity against PHA/IL-2-stimulated human PBMC after 24 hrs by XTT assay2010Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7
Development of hexadecyloxypropyl tenofovir (CMX157) for treatment of infection caused by wild-type and nucleoside/nucleotide-resistant HIV.
AID587747Antiviral activity against single-round HIV1 NLX.Lux-R harboring inactivating mutations in env, vpr and carries firefly luciferase gene in place of nef assessed as level of infection using human HeLaT4 cells pretreated for 24 hrs followed by exposed to vi2011Antimicrobial agents and chemotherapy, Jan, Volume: 55, Issue:1
Identification and characterization of persistent intracellular human immunodeficiency virus type 1 integrase strand transfer inhibitor activity.
AID582417Antiviral activity against Woodchuck hepatitis virus infected in woodchuck assessed as absent of lesion in portal hepatitis at 15 mg/kg, po qd for 48 weeks2008Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10
Antiviral effects of lamivudine, emtricitabine, adefovir dipivoxil, and tenofovir disoproxil fumarate administered orally alone and in combination to woodchucks with chronic woodchuck hepatitis virus infection.
AID587734Antiviral activity against HIV1 NL4-3.Luc assessed as infectivity using human MDM pretreated for 24 hrs followed by exposed to virus after compound washout measured after 2 to 3 days by luciferase assay2011Antimicrobial agents and chemotherapy, Jan, Volume: 55, Issue:1
Identification and characterization of persistent intracellular human immunodeficiency virus type 1 integrase strand transfer inhibitor activity.
AID1636526Therapeutic index, ratio of CC50 for human PBMC to EC50 for HIV1 infected in human PBMC2016Journal of medicinal chemistry, 08-11, Volume: 59, Issue:15
Reduction Sensitive Lipid Conjugates of Tenofovir: Synthesis, Stability, and Antiviral Activity.
AID325085Drug level in human RBC assessed as concentration of tenofovir diphosphate per 10^6 cells after 0.8 hrs2007Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6
Evidence and possible consequences of the phosphorylation of nucleoside reverse transcriptase inhibitors in human red blood cells.
AID1686657Therapeutic index, ratio of CC50 for uninfected human HepG2 cells to EC50 for HBV infected in human HepG2 cells2016Journal of medicinal chemistry, 11-23, Volume: 59, Issue:22
Next-Generation Reduction Sensitive Lipid Conjugates of Tenofovir: Antiviral Activity and Mechanism of Release.
AID541173Selectivity ratio of EC50 for antiviral activity against HIV1 harboring E138K and Q148K mutation in catalytic core domain of integrase to EC50 for antiviral activity against wild-type HIV1 3B2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Preclinical evaluation of GS-9160, a novel inhibitor of human immunodeficiency virus type 1 integrase.
AID572767Antiviral activity against HIV1 infected in human HeLa P4/R5 cells assessed as inhibition of viral replication2009Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9
Anti-human immunodeficiency virus activity, cross-resistance, cytotoxicity, and intracellular pharmacology of the 3'-azido-2',3'-dideoxypurine nucleosides.
AID1599857Selectivity index, ratio of CC50 for human HepG2.2.15 cells to IC50 for HBV infected in human HepG2.2.15 cells2019ACS medicinal chemistry letters, Jun-13, Volume: 10, Issue:6
Design, Synthesis, and Anti-HBV Activity of New Bis(l-amino acid) Ester Tenofovir Prodrugs.
AID325095Ratio of drug level in human RBC to human PBMC assessed as concentration of Lamivudine triphosphate after 0.8 hrs2007Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6
Evidence and possible consequences of the phosphorylation of nucleoside reverse transcriptase inhibitors in human red blood cells.
AID1686654Therapeutic index, ratio of CC50 for uninfected human PBMC to EC50 for HIV1 infected in human PBMC2016Journal of medicinal chemistry, 11-23, Volume: 59, Issue:22
Next-Generation Reduction Sensitive Lipid Conjugates of Tenofovir: Antiviral Activity and Mechanism of Release.
AID541135Selectivity ratio of EC50 for antiviral activity against PI-resistant HIV1 harboring RTG48V, V82A and L90M mutant gene to EC50 for antiviral activity against wild-type HIV1 3B2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Preclinical evaluation of GS-9160, a novel inhibitor of human immunodeficiency virus type 1 integrase.
AID572774Antiviral activity against HIV1 harboring reverse transcriptase K65R mutant infected in human HeLa P4/R5 cells assessed as inhibition of viral replication2009Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9
Anti-human immunodeficiency virus activity, cross-resistance, cytotoxicity, and intracellular pharmacology of the 3'-azido-2',3'-dideoxypurine nucleosides.
AID1457758Antiviral activity against tenofovir-resistant CXCR4-tropic HIV-1 NL4-3 harboring reverse transcriptase K65R mutant infected in human MT4 cells assessed as inhibition of viral replication inhibition of virus-induced cytopathic effect after 6 days by XTT d2017Journal of medicinal chemistry, 07-27, Volume: 60, Issue:14
Expanding the Antiviral Spectrum of 3-Fluoro-2-(phosphonomethoxy)propyl Acyclic Nucleoside Phosphonates: Diamyl Aspartate Amidate Prodrugs.
AID587755Antiviral activity against HIV1 NL4-3.Luc in human MDM assessed as infectivity treated for 24 hrs by luciferase assay2011Antimicrobial agents and chemotherapy, Jan, Volume: 55, Issue:1
Identification and characterization of persistent intracellular human immunodeficiency virus type 1 integrase strand transfer inhibitor activity.
AID541161Selectivity ratio of EC50 for antiviral activity against HIV1 harboring T66I mutation in catalytic core domain of integrase to EC50 for antiviral activity against wild-type HIV1 3B2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Preclinical evaluation of GS-9160, a novel inhibitor of human immunodeficiency virus type 1 integrase.
AID582404Antiviral activity against Woodchuck hepatitis virus infected in woodchuck assessed as reduction of viral DNA replicative intermediate level per ug of total cell DNA at 15 mg/kg, po qd for 48 weeks (Rvb = 995 +/- 736 pg)2008Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10
Antiviral effects of lamivudine, emtricitabine, adefovir dipivoxil, and tenofovir disoproxil fumarate administered orally alone and in combination to woodchucks with chronic woodchuck hepatitis virus infection.
AID587739Cytotoxicity against human HeLaT4 cells by WST-1 assay2011Antimicrobial agents and chemotherapy, Jan, Volume: 55, Issue:1
Identification and characterization of persistent intracellular human immunodeficiency virus type 1 integrase strand transfer inhibitor activity.
AID541129Selectivity ratio of EC50 for antiviral activity against NRTI-resistant HIV1 harboring RTK65R mutant gene to EC50 for antiviral activity against wild-type HIV1 3B2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Preclinical evaluation of GS-9160, a novel inhibitor of human immunodeficiency virus type 1 integrase.
AID572776Antiviral activity against HIV1 harboring reverse transcriptase M184V mutant infected in human HeLa P4/R5 cells assessed as inhibition of viral replication2009Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9
Anti-human immunodeficiency virus activity, cross-resistance, cytotoxicity, and intracellular pharmacology of the 3'-azido-2',3'-dideoxypurine nucleosides.
AID582402Antiviral activity against Woodchuck hepatitis virus infected in woodchuck assessed as reduction of viral antigen level in serum at 15 mg/kg, po qd for 48 weeks (Rvb = 3.8 +/- 1.3 log10 ng/ml)2008Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10
Antiviral effects of lamivudine, emtricitabine, adefovir dipivoxil, and tenofovir disoproxil fumarate administered orally alone and in combination to woodchucks with chronic woodchuck hepatitis virus infection.
AID582423Toxicity in Woodchuck hepatitis virus infected woodchuck assessed as change in body weight at 15 mg/kg, po qd for 48 weeks measured up to 60 weeks2008Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10
Antiviral effects of lamivudine, emtricitabine, adefovir dipivoxil, and tenofovir disoproxil fumarate administered orally alone and in combination to woodchucks with chronic woodchuck hepatitis virus infection.
AID549083Cytotoxicity against human HeLa cells after 24 hrs by XTT assay2010Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7
Development of hexadecyloxypropyl tenofovir (CMX157) for treatment of infection caused by wild-type and nucleoside/nucleotide-resistant HIV.
AID572775Antiviral activity against HIV1 harboring reverse transcriptase L74V mutant infected in human HeLa P4/R5 cells assessed as inhibition of viral replication2009Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9
Anti-human immunodeficiency virus activity, cross-resistance, cytotoxicity, and intracellular pharmacology of the 3'-azido-2',3'-dideoxypurine nucleosides.
AID325090Drug level in human PBMC assessed as concentration of tenofovir diphosphate per 10^6 cells after 0.8 hrs2007Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6
Evidence and possible consequences of the phosphorylation of nucleoside reverse transcriptase inhibitors in human red blood cells.
AID582415Antiviral activity against Woodchuck hepatitis virus infected in woodchuck assessed as frequency of hepatocytes expressing viral antigen at 15 mg/kg, po qd for 48 weeks2008Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10
Antiviral effects of lamivudine, emtricitabine, adefovir dipivoxil, and tenofovir disoproxil fumarate administered orally alone and in combination to woodchucks with chronic woodchuck hepatitis virus infection.
AID572781Ratio of IC50 for HIV1 harboring reverse transcriptase Q151M mutant infected in human HeLa P4/R5 cells to wild type HIV1 infected in human HeLa P4/R5 cells2009Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9
Anti-human immunodeficiency virus activity, cross-resistance, cytotoxicity, and intracellular pharmacology of the 3'-azido-2',3'-dideoxypurine nucleosides.
AID572768Antiviral activity against HIV1 infected in human MT2 cells assessed as inhibition of viral replication2009Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9
Anti-human immunodeficiency virus activity, cross-resistance, cytotoxicity, and intracellular pharmacology of the 3'-azido-2',3'-dideoxypurine nucleosides.
AID572779Ratio of IC50 for HIV1 harboring reverse transcriptase L74V mutant infected in human HeLa P4/R5 cells to wild type HIV1 infected in human HeLa P4/R5 cells2009Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9
Anti-human immunodeficiency virus activity, cross-resistance, cytotoxicity, and intracellular pharmacology of the 3'-azido-2',3'-dideoxypurine nucleosides.
AID541131Selectivity ratio of EC50 for antiviral activity against NRTI-resistant HIV1 harboring RT-6TAMs mutant gene to EC50 for antiviral activity against wild-type HIV1 3B2009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Preclinical evaluation of GS-9160, a novel inhibitor of human immunodeficiency virus type 1 integrase.
AID325097Ratio of drug level in human RBC to human PBMC assessed as concentration of lamivudin triphosphate after 13.5 hrs2007Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6
Evidence and possible consequences of the phosphorylation of nucleoside reverse transcriptase inhibitors in human red blood cells.
AID1686656Cytotoxicity in uninfected human hepG2 assessed as reduction in cell viability by XTT assay2016Journal of medicinal chemistry, 11-23, Volume: 59, Issue:22
Next-Generation Reduction Sensitive Lipid Conjugates of Tenofovir: Antiviral Activity and Mechanism of Release.
AID1636524Antiviral activity against HIV1 infected in human PBMC assessed as inhibition of viral replication by measuring reverse transcriptase activity in cell supernatant preincubated with cells followed by viral infection measured after 7 days by radioactive inc2016Journal of medicinal chemistry, 08-11, Volume: 59, Issue:15
Reduction Sensitive Lipid Conjugates of Tenofovir: Synthesis, Stability, and Antiviral Activity.
AID325084Drug level in human RBC assessed as concentration of tenofovir diphosphate per 10^6 cells after 13.3 hrs2007Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6
Evidence and possible consequences of the phosphorylation of nucleoside reverse transcriptase inhibitors in human red blood cells.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (25)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's8 (32.00)29.6817
2010's9 (36.00)24.3611
2020's8 (32.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 83.07

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index83.07 (24.57)
Research Supply Index3.26 (2.92)
Research Growth Index4.66 (4.65)
Search Engine Demand Index142.04 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (83.07)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other25 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]